How does aurobindo ensure purity in clonazepam manufacturing?

How does Aurobindo ensure purity in clonazepam manufacturing?

Aurobindo Pharma maintains several layers of controls to keep clonazepam batches within specified limits for impurities. The company applies process analytical technology along the manufacturing line and uses online monitoring to track intermediate purity levels. The company also conducts in-process checks every 30-60 minutes during synthesis steps that are prone to degradation products.

What impurities does Aurobindo target in clonazepam synthesis?

Aurobindo focuses on reducing 2-amino-5-chlorobenzophenone and related benzophenone derivatives that can form during the ring-opening reactions. The company sets internal limits below the ICH Q3A and Q3B guidelines, which are tighter than regulatory thresholds. Aurobindo also screens for residual solvents such as dichloromethane and methanol, which are common in benzodiazepine synthesis.

How do Aurobindo’s quality systems meet regulatory expectations?

Aurobindo’s Indian facilities hold FDA-approved status and pass regular inspections by the US FDA, EMA, and UK MHRA. The company’s quality management system follows ICH Q7 guidelines for active pharmaceutical ingredients. It includes supplier audits, raw material testing, and multiple purification steps such as recrystallization and column chromatography. Multiple levels of review before batch release help the company avoid past inspection observations.

When does Aurobindo’s clonazepam patent expire?

Aurobindo does not hold the basic compound patent on clonazepam. The original compound patent filed by Hoffmann-La Roche expired decades ago. Aurobindo holds formulation or process patents that may still be active. Those patents typically expire 20 years from filing, so any active ones are likely to end around 2030.